Severe de novo Ulcerative Colitis following Ixekizumab Therapy

Ixekizumab is a selective monoclonal antibody targeting interleukin-17A, approved for the treatment of chronic plaque psoriasis. It has rarely been associated with inflammatory bowel disease (IBD) in randomized trials only. We report a unique case of severe new-onset ulcerative colitis in a young ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Philipose, Jobin, Ahmed, Moiz, Idiculla, Pretty S., Mulrooney, Stephen M., Gumaste, Vivek V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244035/
https://www.ncbi.nlm.nih.gov/pubmed/30483039
http://dx.doi.org/10.1159/000493922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244035/
https://www.ncbi.nlm.nih.gov/pubmed/30483039
http://dx.doi.org/10.1159/000493922

Ejemplares similares